|
66 Companies |
|
64 Products |
|
64 Products |
|
38 Mechanisms of Action |
|
0 Trials |
|
1523 News |
|
| «12...1920212223242526272829...3031» |
- Fluzone (influenza vaccine) / Sanofi, Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
Trial completion: Atopic Dermatitis Research Network (ADRN) Influenza Vaccine Pilot (clinicaltrials.gov) - Nov 27, 2012
P0, N=40, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Completed
- Trial completion: A Study to Determine the Safety and Immunogenicity of Co-administration of the Candidate Influenza Vaccine MVA-NP+M1 and Seasonal Influenza Vaccine (clinicaltrials.gov) - Nov 27, 2012
P1, N=24, Completed, Sponsor: University of Oxford
Recruiting --> Completed Active, not recruiting --> Completed
- Trial completion: A Study to Assess the Safety and Immunogenicity of a New Influenza Vaccine Candidate MVA-NP+M1 in Healthy Adults (clinicaltrials.gov) - Nov 27, 2012
P1, N=58, Completed, Sponsor: University of Oxford
Active, not recruiting --> Completed Active, not recruiting --> Completed
- |||| PANFLU.1 (influenza A H1N1 influenza virus split vaccine) / Sinovac, PanFlu (influenza H5N1 vaccine) / Sinovac, Anflu (trivalent influenza virus split vaccine) / Sinovac
Trial completion: Sinovac, H1N1 Vaccine + Trivalent Inactivated Influenza Vaccine, Adults (clinicaltrials.gov) - Nov 25, 2012
P4, N=150, Completed, Sponsor: Sinovac Biotech Co., Ltd
Active, not recruiting --> Completed Recruiting --> Completed
- Clinical: Immune Response to Vaccination in Patients Receiving Single Drug Immunosuppression (clinicaltrials.gov) - Nov 22, 2012
P=N/A, N=30, Recruiting, Sponsor: Emory University
- Trial completion, Review: A Systematic Review of Studies of the Effect of Influenza Vaccine Against Mismatched Strains (clinicaltrials.gov) - Nov 20, 2012
P=N/A, N=1, Completed, Sponsor: GlaxoSmithKline
Recruiting --> Completed Active, not recruiting --> Completed
- ||||| Fluarix (influenza virus trivalent vaccine) / GSK
New P4 trial: Immunogenicity and Safety of PrepandrixTM in Korean Subjects Aged 18 to 60 Years Old (clinicaltrials.gov) - Nov 19, 2012
P4, N=131, Completed, Sponsor: GlaxoSmithKline
- | favipiravir / Generic mfg.
New P1/2 trial: T-705a Multicenter Study in Adults Subjects With Uncomplicated Influenza (clinicaltrials.gov) - Nov 18, 2012
P1/2, N=550, Completed, Sponsor: FujiFilm Pharmaceuticals U.S.A., Inc.
- ||||||| Agriflu (trivalent influenza virus vaccine) / CSL Behring
Trial completion: Safety, Tolerability, and Immunogenicity of the Adjuvanted Trivalent Subunit Influenza Vaccine and the Non-Adjuvanted Trivalent Subunit Influenza Vaccine Compared to the Non-Adjuvanted Trivalent Split Influenza Vaccine in Children 6 to < 72 Months of Age (clinicaltrials.gov) - Nov 15, 2012
P3, N=6105, Completed, Sponsor: Novartis Vaccines
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | New P4 trial: Effectiveness of a Handwashing Programme in the Prevention of School Absenteeism Due to Respiratory Infections (clinicaltrials.gov) - Nov 14, 2012
P4, N=1640, Completed, Sponsor: Fundación Pública Andaluza para la Investigación Biomédica Andalucía Oriental
- | Rapivab (peramivir) / BioCryst
Trial termination: A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza (clinicaltrials.gov) - Nov 11, 2012
P3, N=406, Terminated, Sponsor: BioCryst Pharmaceuticals
Active, not recruiting --> Completed Recruiting --> Terminated; This study was terminated for futility
- | Rapivab (peramivir) / BioCryst
Enrollment change: A Study to Evaluate the Efficacy and Safety of IV Peramivir in Addition to Standard of Care Compared to Standard of Care Alone in Adults and Adolescents Who Are Hospitalized Due to Influenza (clinicaltrials.gov) - Nov 11, 2012
P3, N=406, Terminated, Sponsor: BioCryst Pharmaceuticals
Recruiting --> Terminated; This study was terminated for futility N=600 --> 406
- oseltamivir / Generic mfg.
Enrollment change: Efficacy Study of Early Versus Late Oseltamivir Administration for Treating and Preventing Influenza (clinicaltrials.gov) - Nov 11, 2012
P=N/A, N=194, Terminated, Sponsor: Marshfield Clinic Research Foundation
N=600 --> 406 N=400 --> 194
- |||| Trial completion: Study to Evaluate the Immunogenicity and Safety of an Investigational Pandemic Influenza Vaccine in Children (clinicaltrials.gov) - Nov 7, 2012
P2, N=113, Completed, Sponsor: GlaxoSmithKline
N=400 --> 194 Active, not recruiting --> Completed
- Trial completion: Safety of Lactobacillus Rhamnosus GG Vs. Placebo in Elderly Subjects Receiving Trivalent Inactivated Influenza Vaccine (clinicaltrials.gov) - Nov 5, 2012
P1, N=28, Completed, Sponsor: Massachusetts General Hospital
Active, not recruiting --> Completed Active, not recruiting --> Completed
- | Trial termination: Study to Evaluate the Safety and Immunogenicity of GSK Biological Pandemic Candidate Influenza Vaccine (H1N1) in Children (clinicaltrials.gov) - Oct 31, 2012
P3, N=60, Terminated, Sponsor: GlaxoSmithKline
Active, not recruiting --> Completed Completed --> Terminated
- | Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P4 trial: High Dose Influenza Vaccine in Nursing Home - Pilot Study (clinicaltrials.gov) - Oct 31, 2012
P4, N=210, Active, not recruiting, Sponsor: Insight Therapeutics, LLC
- ||||||| Havrix (hepatitis A vaccine, inactivated) / GSK
Trial completion: A Study to Evaluate the Safety and Immunogenicity of a Prime-boost Schedule of GSK Biologicals' Influenza Vaccine in Children (clinicaltrials.gov) - Oct 31, 2012
P3, N=520, Completed, Sponsor: GlaxoSmithKline
Completed --> Terminated Active, not recruiting --> Completed
- influenza vaccine (FLU-v) / ConserV Biosci, Imutex
Enrollment change: Influenza Vaccine Challenge Study in Healthy Subjects (clinicaltrials.gov) - Oct 31, 2012
P1, N=32, Completed, Sponsor: PepTcell Limited
Active, not recruiting --> Completed N=44 --> 32
- | influenza vaccine (FLU-v) / ConserV Biosci, Imutex
Trial completion: Influenza Vaccine Challenge Study in Healthy Subjects (clinicaltrials.gov) - Oct 31, 2012
P1, N=32, Completed, Sponsor: PepTcell Limited
N=44 --> 32 Active, not recruiting --> Completed
- New P1 trial: Reactogenicity, Safety, and Immunogenicity of a Live Monovalent H5N2 Influenza Vaccine (clinicaltrials.gov) - Oct 30, 2012
P1, N=40, Completed, Sponsor: Program for Appropriate Technology in Health
- Enrollment change: Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Oct 29, 2012
P=N/A, N=9, Completed, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed N=400 --> 9
- Trial completion: Surveillance of Influenza Virus Shedding and Immunologic Response in Immunocompromised Children and Young Adults (clinicaltrials.gov) - Oct 29, 2012
P=N/A, N=9, Completed, Sponsor: St. Jude Children's Research Hospital
N=400 --> 9 Recruiting --> Completed
- VGX-3400X / GeneOne, Inovio
Enrollment change: A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 (clinicaltrials.gov) - Oct 25, 2012
P1, N=22, Completed, Sponsor: Inovio Pharmaceuticals
Recruiting --> Completed N=30 --> 22
- | oseltamivir / Generic mfg.
New P1 trial: A Pharmacokinetic/Pharmacodynamic Study of Oseltamivir in Immunocompromised Children With Confirmed Influenza Infection (clinicaltrials.gov) - Oct 25, 2012
P1, N=20, Recruiting, Sponsor: Hoffmann-La Roche
- | VGX-3400X / GeneOne, Inovio
Trial completion: A Follow-On Study With an H5 Influenza Vaccine for Subjects Who Participated in Study FLU-001 (clinicaltrials.gov) - Oct 25, 2012
P1, N=22, Completed, Sponsor: Inovio Pharmaceuticals
N=30 --> 22 Active, not recruiting --> Completed
- Fluzone High-Dose Quadrivalent (influenza vaccine) / Evotec, Sanofi
Enrollment closed: Immunogenicity of Fluzone HD,A High Dose Influenza Vaccine, In Children With Cancer or HIV (clinicaltrials.gov) - Oct 23, 2012
P2, N=280, Active, not recruiting, Sponsor: St. Jude Children's Research Hospital
Active, not recruiting --> Completed Recruiting --> Active, not recruiting
- |||||||||| Fluzone Intradermal Quadrivalent (influenza vaccine) / Evotec, Sanofi
New P3 trial: Study of Intradermal Quadrivalent Influenza Vaccine in Adults Aged 18 Through 64 Years (clinicaltrials.gov) - Oct 22, 2012
P3, N=3360, Completed, Sponsor: Sanofi Pasteur, a Sanofi Company
- New P1/2 trial: SCID Bu/Flu/ATG Study With T Cell Depletion (clinicaltrials.gov) - Oct 18, 2012
P1/2, N=15, Enrolling by invitation, Sponsor: Neena Kapoor, M.D.
- Fluzone (influenza vaccine) / Sanofi
Enrollment change: Comparison of Flu Vaccine Doses in Children (clinicaltrials.gov) - Oct 17, 2012
P1, N=243, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
Recruiting --> Active, not recruiting N=330 --> 243
- Fluzone (influenza vaccine) / Sanofi
Trial completion: Comparison of Flu Vaccine Doses in Children (clinicaltrials.gov) - Oct 17, 2012
P1, N=243, Completed, Sponsor: National Institute of Allergy and Infectious Diseases (NIAID)
N=330 --> 243 Recruiting --> Completed
- oseltamivir / Generic mfg.
Trial initiation date: Oseltamivir for Influenza Lower Respiratory Tract Infection in Children Under One (clinicaltrials.gov) - Oct 16, 2012
P2/3, N=0, Withdrawn, Sponsor: University of Oxford
Recruiting --> Completed Initiation date: Jun 2012 --> Dec 2012
- |||| Trial completion: Open-label Study to Assess Immunogenicity and Safety of a Vaccine Enhancement Patch When Administered With 2 Doses of H5N1 Vaccine (clinicaltrials.gov) - Oct 16, 2012
P1/2, N=276, Completed, Sponsor: Intercell USA, Inc.
Initiation date: Jun 2012 --> Dec 2012 Active, not recruiting --> Completed
- ||| New P1 trial: RSV-F Vaccine and Influenza Vaccine Co-Administration Study in the Elderly (clinicaltrials.gov) - Oct 15, 2012
P1, N=220, Completed, Sponsor: Novavax
- Enrollment change: Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=3988, Completed, Sponsor: Duke University
Active, not recruiting --> Completed N=1540 --> 3988
- | Vaxigrip (inactivated influenza vaccine (split virion)) / Sanofi
New P1/2 trial: FLUWAY: Routes of Immunization and Flu Immune Responses (clinicaltrials.gov) - Oct 14, 2012
P1/2, N=60, Completed, Sponsor: Assistance Publique - Hôpitaux de Paris
- Trial completion: Effectiveness of a Vaccination Program in the Community Ob/Gyn Setting (clinicaltrials.gov) - Oct 14, 2012
P=N/A, N=3988, Completed, Sponsor: Duke University
N=1540 --> 3988 Recruiting --> Completed
- ||| Betaseron (IFN-β-1b) / Bayer
Clinical: Assessment of Strategies for the Management of Flu-like Symptoms in MS Patients Commencing Treatment With Betaferon (INFLUENCE) (clinicaltrials.gov) - Oct 11, 2012
P=N/A, N=650, Recruiting, Sponsor: Bayer
- |||| Trial completion: Yearly Licence Tolerability and Immunogenicity Study of Fluval AB Seasonal Influenza Vaccine to be Used in the 2012/2013 Vaccination Season (clinicaltrials.gov) - Oct 10, 2012
P4, N=120, Completed, Sponsor: Omninvest Vaccine Manufacturing, Researching and Trading Ltd.
Recruiting --> Completed Not yet recruiting --> Completed
- || oseltamivir / Generic mfg.
Enrollment change: A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection (clinicaltrials.gov) - Oct 9, 2012
P1, N=58, Completed, Sponsor: Hoffmann-La Roche
Not yet recruiting --> Completed N=84 --> 58
- ||| oseltamivir / Generic mfg.
Trial completion: A Pharmacokinetic/Pharmacodynamic (PK/PD) and Safety Evaluation of Oseltamivir [Tamiflu] in the Treatment of Infants 0 to <12 Months of Age With Confirmed Flu Infection (clinicaltrials.gov) - Oct 9, 2012
P1, N=58, Completed, Sponsor: Hoffmann-La Roche
N=84 --> 58 Recruiting --> Completed
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Enrollment change: Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants (clinicaltrials.gov) - Oct 7, 2012
P4, N=3, Completed, Sponsor: University of Rochester
Recruiting --> Completed N=28 --> 3
- FluMist (influenza vaccine, live, intranasal) / AstraZeneca, Fluzone (influenza vaccine) / Sanofi, FluMist Quadrivalent (live attenuated influenza vaccine nasal spray) / AstraZeneca, Daiichi Sankyo
Trial completion: Study of Live, Attenuated Influenza Vaccination in Preterm and Full-Term Infants (clinicaltrials.gov) - Oct 7, 2012
P4, N=3, Completed, Sponsor: University of Rochester
N=28 --> 3 Recruiting --> Completed
- || Fluarix Quadrivalent (influenza vaccine) / GSK
New P3 trial: Immunogenicity and Safety Study of GlaxoSmithKline (GSK) Biologicals' Influenza Vaccine When Administered in Children Who Previously Participated in Study 115345 (clinicaltrials.gov) - Oct 4, 2012
P3, N=468, Completed, Sponsor: GlaxoSmithKline
- oseltamivir / Generic mfg.
Enrollment change: Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation (clinicaltrials.gov) - Oct 3, 2012
P4, N=6, Completed, Sponsor: Pharmahungary Group
Recruiting --> Completed N=20 --> 6
- oseltamivir / Generic mfg.
Trial completion: Observational Study on the Pharmacokinetics of Oseltamivir in the Treatment of Influenza During Lactation (clinicaltrials.gov) - Oct 3, 2012
P4, N=6, Completed, Sponsor: Pharmahungary Group
N=20 --> 6 Recruiting --> Completed
- ||| New P1 trial: Influenza A Vaccine (FP-01.1) Formulated With and Without Adjuvant, in the Presence or Absence of a Single Administration of a Trivalent Inactivated Influenza Virus Vaccine in Older Adults (clinicaltrials.gov) - Oct 3, 2012
P1, N=120, Completed, Sponsor: Immune Targeting Systems Ltd
- Enrollment closed: Immune Responses Induced by Different Licensed Influenza Vaccines (clinicaltrials.gov) - Oct 2, 2012
P=N/A, N=36, Active, not recruiting, Sponsor: University of Massachusetts, Worcester
Recruiting --> Completed Recruiting --> Active, not recruiting
- Enrollment closed: Effect of the Consumption of a Fermented Dairy Drink on the Immune Function (clinicaltrials.gov) - Sep 30, 2012
P=N/A, N=0, Active, not recruiting, Sponsor: Danone Research
Recruiting --> Active, not recruiting Recruiting --> Active, not recruiting
- | Vimizim (elosulfase alfa) / BioMarin
New P2 trial: Efficacy and Safety Study of BMN 110 for Morquio A Syndrome Patients Who Have Limited Ambulation (clinicaltrials.gov) - Sep 30, 2012
P2, N=15, Active, not recruiting, Sponsor: BioMarin Pharmaceutical